MPM BioImpact’s Compass Therapeutics CMPX Stock Holding History

MPM BioImpact’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,075,970	Closed	-$17.8M	–	42
2025 Q3	$17.8M	Sell	5,075,970 -546,535	-10%	-$1.73M	2.91%	14
2025 Q2	$14.6M	Sell	5,622,505 -2,820,278	-33%	-$5.82M	2.53%	15
2025 Q1	$16M	Sell	8,442,783 -125,113	-1%	-$333K	2.76%	14
2024 Q4	$12.4M	Buy	8,567,896 +2,926,002	+52%	+$4.86M	1.76%	27
2024 Q3	$10.4M	Buy	5,641,894 +636,808	+13%	+$794K	1.56%	23
2024 Q2	$5.01M	Buy	5,005,086 +3,033,684	+154%	+$4.43M	0.78%	39
2024 Q1	$3.9M	Buy	+1,971,402	New	+$3.41M	0.63%	38

Other funds holding CMPX

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blackstone Inc New York $24.2B AUM 26.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return